Oncolytic Virus-Based Gene Therapy Market Revenue and Forecast by 2033

13 Oct 2025

Share :

Table of Content

1. Oncolytic Virus-Based Gene Therapy Market Revenue and Trends 2025 to 2033 2. Overview of Market Growth and Key Drivers for Oncolytic Virus-Based Gene Therapy 3. Segmental Analysis 4. Regional Insights 5. Market Coverage 6. Recent Developments 7. Key Players in Oncolytic Virus-Based Gene Therapy Market

Oncolytic Virus-Based Gene Therapy Market Revenue and Trends 2025 to 2033

The oncolytic virus-based gene therapy market is gaining momentum with rising cancer prevalence, expanding clinical trials, and strong investment in precision immunotherapies. The oncolytic virus-based gene therapy market is driven by rising cancer prevalence, expanding clinical trials, and increasing adoption of targeted immunotherapy solutions.

Overview of Market Growth and Key Drivers for Oncolytic Virus-Based Gene Therapy

The market for gene therapy using oncolytic viruses is growing steadily as a result of the increasing incidence of cancer and advancements in the technologies used to engineer viruses. This market pertains to genetically engineered viruses that preferentially infect and kill cancer cells while stimulating the immune system. Oncolytic viruses are a combination therapy; they can directly lyse tumor cells and deliver therapeutic gene to augment anti-tumor activity.

Market expansion is being fueled by growing investments in oncology research, favorable regulation, and clinical studies that are testing viruses in combination with immunotherapies. Furthermore, increased interest from biotechnology and academia is supporting the emerging long-term market development and commercialization..

Segmental Analysis

• By Virus Type- Due to its strong oncolytic properties, genetic stability, and its ability to preferentially infect and kill tumor cells while sparing normal healthy cells, the Herpes Simplex Virus (HSV) is the largest market segment.
• By Route of Administration- The largest segment is intravenous administration due to the ability to provide systemic exposure, maximizing the potential for effective tumor targeting for the treatment of primary and metastatic cancers.
• By Cancer Type- Melanoma is the largest market segment due to the clinical efficacy and regulatory approval of HSV-based therapies, especially T-VEC for the treatment of advanced melanoma cases.
• By End User- Pharmaceutical and biotechnology companies are the largest segment, as they perform a tremendous amount of R&D, clinical trials, and commercialization of oncolytic virus-based gene therapies.

Regional Insights

North America is dominating in oncolytic-virus gene therapy, attributable to early regulatory achievements, concentration of biotechs, and world-class cancer centres. The FDA approval of talimogene laherparepvec (T-VEC/Imlygic), along with dense early-phase trial activity, has anchored translational pipelines, enabling significant academia-to-industry cooperation, enhanced manufacturing capacity, and more predictable recruitment of patients. Collectively, these capabilities provide an environment in which studies can protocolized more swiftly, safety and efficacy studies can be done reliably, and the clinical landscape can continue to be led by the US.

Asia Pacific is the fastest-growing region for oncolytic-virus therapies, driven by the growing domestic R&D, large patient populations in oncology that can shorten patient recruitment timelines, and regulatory pathways that continue to how favourably to biologics. The region's early clinical experience, combined with the emergence of rapid trial activity in China, Japan, and South Korea, has enhanced local development ability, scale-up of manufacturing, and cross-border collaboration which collectively have accelerated maturation of pipelines and expanded local availability.

Market Coverage

Recent Developments

• In May 2025, Tilt Biotherapeutics raised US$25.6 million in a series B to advance its experimental oncolytic adenovirus therapy into a Phase II trial for platinum-resistant ovarian cancer (PROC). It is designed to give in combination with T cell–based therapies such as tumour-infiltrating lymphocytes (TILs) or checkpoint inhibitors to boost their efficacy. (Source: https://firstwordpharma.com)

Key Players in Oncolytic Virus-Based Gene Therapy Market

• Amgen Inc.
• Replimune Group, Inc.
• Oncolytics Biotech Inc.
• SillaJen, Inc.
• Viralytics Ltd.
• Targovax ASA
• Oncorus, Inc.
• Lokon Pharma
• Virogin Biotech
• Transgene SA

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6975

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344